Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers
Complete Title: A phase 1b/2 dose escalation and expansion study of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy for HER2+ gastrointestinal cancers
Trial Phase: I/II
Investigator: David Zhen
This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (FOLFOX and CAPOX). It will look at what side effects happen when participants take this combination of drugs. A side effect is anything the drug does other than treating cancer. It will also look at whether tucatinib works with these drugs to treat certain types of cancer. The participants in this trial have HER2-positive (HER2+) cancer in their gut, stomach, intestines, or gallbladder (gastrointestinal cancer).
Keywords:
- Esophageal Cancer
- Gastric Cancer
- Adenocarcinoma
- Colorectal Neoplasms
- Cholangiocarcinoma
- Gastroesophageal Junction Cancer
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
David Zhen
RG1121050
NCT04430738
A phase 1b/2 dose escalation and expansion study of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy for HER2+ gastrointestinal cancers
Esophageal Cancer
Gastric Cancer
Adenocarcinoma
Colorectal Neoplasms
Cholangiocarcinoma
Gastroesophageal Junction Cancer